Improvements to Gene Therapy Clinical Trial Design Benefit Hemophilia Patients
Gene Therapy Allows Hemophilia Patients to Give Up Medication, Avoid Bleeds; but More Improvements Are Needed
To Gild the Microbe Is Anything but Wasteful
Synthetic Biology Is Enabling Optimization that Is Iterative—and Remunerative
Turning Cell Signaling against Cancer
Researchers Use Single-Molecule Assays, Splice-Switching Oligonucleotides, and Fusion Constructs
Viral Safety Copes with Complexity
Viral Clearance Calls for Bioprocess Engineers to Implement Control Strategies
Colette Cote Ph.D.
Colette Côté, Ph.D., is principal scientist, head of next-generation sequencing and bioinformatics, development services at the BioReliance® portfolio of MilliporeSigma.